Yuichiro Minami
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yuichiro Minami has a total of 241 co-authors. Here are the top co-authors by number of shared publications:
Nobuhisa Hagiwara
Department of Cardiology, Tokyo Women's Medical University, Tokyo, Japan
38 shared publicationsShintaro Haruki
Department of Cardiology, Tokyo Women’s Medical University, Tokyo, Japan
32 shared publicationsJunichi Yamaguchi
Department of Cardiology, Tokyo Women’s Medical University, Tokyo, Japan
10 shared publications- Kentaro Jujo
Department of Cardiology, Tokyo Women's Medical University, Tokyo, Japan; Department of Cardiology, Saitama Medical University, Saitama Medical Center, Saitama, Japan
9 shared publications Chihiro Saito
Department of Cardiology, Tokyo Women's Medical University, Tokyo, Japan
7 shared publicationsHidetoshi Hattori
Department of Cardiology, Tokyo Women’s Medical University, Tokyo, Japan
7 shared publications
Latest Publications
- 19 August 2026
- Published by Springer Nature in Heart and Vessels
- p. 1-2
Reply to “Acute heart failure and interleukin-6: Biomarker, bystander, or therapeutic target?”
- 19 August 2026
- Published by Springer Nature in Heart and Vessels
- p. 1-2
Reply to “Acute heart failure and interleukin-6: Biomarker, bystander, or therapeutic target?”
- 10 August 2026
- Published by Springer Nature in Heart and Vessels
- p. 1-2
Reply to “Interleukin-6 in acute heart failure: a marker of phenotype-specific biology or multimorbidity?”
- 10 August 2026
- Published by Springer Nature in Heart and Vessels
- p. 1-2
Reply to “Interleukin-6 in acute heart failure: a marker of phenotype-specific biology or multimorbidity?”
- Open Access
- 30 June 2026
- Published by Springer Nature in Heart and Vessels
- p. 1-9
Differential prognostic impact of interleukin-6 in acute heart failure with reduced versus preserved ejection fraction
Interleukin-6 (IL-6) plays a role in acute heart failure (AHF) and can predict death and re-hospitalization. However, the relationship between IL-6 levels and mortality, based on heart failure phenotype, remains unclear. This study aimed to clarify the association between IL-6 levels and mortality in patients with AHF with reduced ejection fraction (HFrEF) and with preserved ejection fraction (HFpEF). A retrospective observational study was conducted on 371 AHF cases admitted to our institution. Patients were categorized into two groups based on IL-6 levels using Receiver Operating Characteristic (ROC) curve analysis: those with IL-6 below 29.0 pg/mL (N = 239) and those above 29.0 pg/mL (N = 132). Mortality rates were assessed for both HFrEF and HFpEF patients to determine the differential impact of IL-6. The average age was 71 years, with 60% male. Over a median follow-up of 222 days, 53 patients (14.8%) died. Kaplan–Meier analysis revealed a significantly higher mortality rate in patients with IL-6 levels above 29.0 pg/mL (P < 0.001). Elevated IL-6 levels were associated with increased mortality in both categories of left ventricular ejection fraction. In particular, among patients with HFrEF, those with elevated IL-6 levels exhibited a higher risk of death after 30 days (P = 0.017), while HFpEF patients with elevated IL-6 levels had a higher risk of death within 30 days (P = 0.002). Elevated IL-6 levels predicted higher all-cause mortality in both HFrEF and HFpEF patients. The effect of elevated IL-6 on mortality varies between short-term and long-term implications for HFrEF and HFpEF.
- 30 June 2026
- Published by Springer Nature in Heart and Vessels
- p. 1-9
Open AccessDifferential prognostic impact of interleukin-6 in acute heart failure with reduced versus preserved ejection fraction
Interleukin-6 (IL-6) plays a role in acute heart failure (AHF) and can predict death and re-hospitalization. However, the relationship between IL-6 levels and mortality, based on heart failure phenotype, remains unclear. This study aimed to clarify the association between IL-6 levels and mortality in patients with AHF with reduced ejection fraction (HFrEF) and with preserved ejection fraction (HFpEF). A retrospective observational study was conducted on 371 AHF cases admitted to our institution. Patients were categorized into two groups based on IL-6 levels using Receiver Operating Characteristic (ROC) curve analysis: those with IL-6 below 29.0 pg/mL (N = 239) and those above 29.0 pg/mL (N = 132). Mortality rates were assessed for both HFrEF and HFpEF patients to determine the differential impact of IL-6. The average age was 71 years, with 60% male. Over a median follow-up of 222 days, 53 patients (14.8%) died. Kaplan–Meier analysis revealed a significantly higher mortality rate in patients with IL-6 levels above 29.0 pg/mL (P < 0.001). Elevated IL-6 levels were associated with increased mortality in both categories of left ventricular ejection fraction. In particular, among patients with HFrEF, those with elevated IL-6 levels exhibited a higher risk of death after 30 days (P = 0.017), while HFpEF patients with elevated IL-6 levels had a higher risk of death within 30 days (P = 0.002). Elevated IL-6 levels predicted higher all-cause mortality in both HFrEF and HFpEF patients. The effect of elevated IL-6 on mortality varies between short-term and long-term implications for HFrEF and HFpEF.
- 19 May 2026
- Published by Elsevier in Journal of Cardiology
Serum chloride level and outcome in patients with hypertrophic cardiomyopathy
- 19 May 2026
- Published by Elsevier in Journal of Cardiology
Serum chloride level and outcome in patients with hypertrophic cardiomyopathy
- Open Access
- 29 November 2025
- Published by International Heart Journal (Japanese Heart Journal) in International Heart Journal
- Vol. 66 (6) , 956-960
Long-Term Prognostic Value of Albumin-Bilirubin Score at Discharge in Patients with Acute Heart Failure
Liver dysfunction is associated with poorer outcomes in patients with heart failure (HF). The albumin-bilirubin (ALBI) score, which combines serum albumin and total bilirubin levels, has recently emerged as a useful tool to assess liver function and predict prognosis, yet its role in predicting long-term outcomes in patients with acute heart failure (AHF) remains unclear.A total of 492 patients with AHF who were admitted to our hospital were included in the study. The patients were divided into two groups based on their ALBI score at discharge: < -2.25 and ≥ -2.25. The primary endpoint was a composite of all-cause mortality and rehospitalization for HF.The mean age of the patients was 70 years, and 63% were male. During a median follow-up period of 189 days, patients with an ALBI score ≥ -2.25 had a significantly higher risk of the composite endpoint compared to those with an ALBI score < -2.25 (17.0% versus 7.4%, respectively; HR: 1.82, 95% CI: 1.34-2.49; P < 0.001). Multivariable Cox proportional hazards models confirmed that an ALBI score ≥ -2.25 was an independent predictor of poor outcomes, even after adjusting for factors related to HF (HR: 2.00, 95% CI: 1.29-3.13; P = 0.002).The ALBI score at discharge may be useful for risk stratification of all-cause mortality and rehospitalization for HF in patients with AHF.
- 29 November 2025
- Published by International Heart Journal (Japanese Heart Journal) in International Heart Journal
- Vol. 66 (6) , 956-960
Open AccessLong-Term Prognostic Value of Albumin-Bilirubin Score at Discharge in Patients with Acute Heart Failure
Liver dysfunction is associated with poorer outcomes in patients with heart failure (HF). The albumin-bilirubin (ALBI) score, which combines serum albumin and total bilirubin levels, has recently emerged as a useful tool to assess liver function and predict prognosis, yet its role in predicting long-term outcomes in patients with acute heart failure (AHF) remains unclear.A total of 492 patients with AHF who were admitted to our hospital were included in the study. The patients were divided into two groups based on their ALBI score at discharge: < -2.25 and ≥ -2.25. The primary endpoint was a composite of all-cause mortality and rehospitalization for HF.The mean age of the patients was 70 years, and 63% were male. During a median follow-up period of 189 days, patients with an ALBI score ≥ -2.25 had a significantly higher risk of the composite endpoint compared to those with an ALBI score < -2.25 (17.0% versus 7.4%, respectively; HR: 1.82, 95% CI: 1.34-2.49; P < 0.001). Multivariable Cox proportional hazards models confirmed that an ALBI score ≥ -2.25 was an independent predictor of poor outcomes, even after adjusting for factors related to HF (HR: 2.00, 95% CI: 1.29-3.13; P = 0.002).The ALBI score at discharge may be useful for risk stratification of all-cause mortality and rehospitalization for HF in patients with AHF.
- Open Access
- 10 November 2025
- Published by Japanese Circulation Society in Circulation Reports
- Vol. 7 (11) , 997-1004
Diagnostic Accuracy of the Initial Point-of-Care Troponin Tests for Patients With Chest Pain Who Were Suspected of Acute Myocardial Infarction ― A Systematic Review and Meta-Analysis ―
Background: Point-of-care (POC) cardiac troponin testing, although less sensitive than high-sensitivity cardiac troponin assays, allows for rapid bedside evaluation. This study assessed the diagnostic performance of POC troponin tests for both ruling in and ruling out acute myocardial infarction (AMI) at the time of patient presentation.Methods and Results: In accordance with PRISMA-DTA guidelines, we conducted a systematic review and meta-analysis using PubMed, Web of Science, and the Cochrane Library from inception through June 17, 2023. We included all studies evaluating the diagnostic accuracy of POC troponin assays for identifying AMI among adult patients. Among the 551 studies initially screened, 6 met the eligibility criteria for inclusion. A meta-analysis of diagnostic accuracy based on these 6 observational datasets demonstrated pooled sensitivity and specificity values of 47% (95% confidence interval (CI) 45–49%) and 90% (95% CI 89–90%), respectively, for AMI detection. In a subgroup meta-analysis of non-ST-segment elevation MI using 4 observational datasets, the pooled sensitivity and specificity were 48% (95% CI 45–50%) and 89% (95% CI 89–90%), respectively.Conclusions: These findings emphasize that the clinical application of POC troponin assays in AMI diagnosis must consider the test’s robust specificity (≈90%) alongside its limited sensitivity (<50%).
- 10 November 2025
- Published by Japanese Circulation Society in Circulation Reports
- Vol. 7 (11) , 997-1004
Open AccessDiagnostic Accuracy of the Initial Point-of-Care Troponin Tests for Patients With Chest Pain Who Were Suspected of Acute Myocardial Infarction ― A Systematic Review and Meta-Analysis ―
Background: Point-of-care (POC) cardiac troponin testing, although less sensitive than high-sensitivity cardiac troponin assays, allows for rapid bedside evaluation. This study assessed the diagnostic performance of POC troponin tests for both ruling in and ruling out acute myocardial infarction (AMI) at the time of patient presentation.Methods and Results: In accordance with PRISMA-DTA guidelines, we conducted a systematic review and meta-analysis using PubMed, Web of Science, and the Cochrane Library from inception through June 17, 2023. We included all studies evaluating the diagnostic accuracy of POC troponin assays for identifying AMI among adult patients. Among the 551 studies initially screened, 6 met the eligibility criteria for inclusion. A meta-analysis of diagnostic accuracy based on these 6 observational datasets demonstrated pooled sensitivity and specificity values of 47% (95% confidence interval (CI) 45–49%) and 90% (95% CI 89–90%), respectively, for AMI detection. In a subgroup meta-analysis of non-ST-segment elevation MI using 4 observational datasets, the pooled sensitivity and specificity were 48% (95% CI 45–50%) and 89% (95% CI 89–90%), respectively.Conclusions: These findings emphasize that the clinical application of POC troponin assays in AMI diagnosis must consider the test’s robust specificity (≈90%) alongside its limited sensitivity (<50%).
- 12 August 2025
- Published by Springer Nature in Heart and Vessels
- Vol. 41 (2) , 96-103
Modified nutrition risk in critically ill (mNUTRIC) score on admission and mortality in acute heart failure patients admitted to the cardiac intensive care unit
The modified nutrition risk in critically ill (mNUTRIC) score was developed to quantify the risk of adverse events related to malnutrition in the intensive care unit setting. However, its prognostic value has not been examined in patients with acute heart failure (AHF). This study aimed to investigate the relationship between mNUTRIC score and all-cause mortality in AHF patients in the cardiac intensive care unit (CCU). We retrospectively examined 307 patients with AHF who were admitted to our CCU from April 2014 to March 2017. mNUTRIC score was calculated within 24 h of CCU admission. Patients were classified as either high nutritional risk (score ≥ 5) or low nutritional risk (score < 5). The primary endpoint was death from any cause. Median follow-up was 272 days (interquartile range 59-588). Kaplan-Meier survival analysis showed that overall survival was significantly worse in the high nutritional risk group (p < 0.001). In the multivariate analysis adjusted for chronic kidney disease, systolic blood pressure, hypoalbuminemia, anemia, and C-reactive protein concentration, mNUTRIC score ≥ 5 was an independent predictor of higher all-cause mortality (adjusted hazard ratio, 2.23; 95% confidence interval, 1.33-3.72; p = 0.003). mNUTRIC score ≥ 5 at admission to the CCU is associated with increased risk of mortality in AHF patients in the CCU.
- 12 August 2025
- Published by Springer Nature in Heart and Vessels
- Vol. 41 (2) , 96-103
Modified nutrition risk in critically ill (mNUTRIC) score on admission and mortality in acute heart failure patients admitted to the cardiac intensive care unit
The modified nutrition risk in critically ill (mNUTRIC) score was developed to quantify the risk of adverse events related to malnutrition in the intensive care unit setting. However, its prognostic value has not been examined in patients with acute heart failure (AHF). This study aimed to investigate the relationship between mNUTRIC score and all-cause mortality in AHF patients in the cardiac intensive care unit (CCU). We retrospectively examined 307 patients with AHF who were admitted to our CCU from April 2014 to March 2017. mNUTRIC score was calculated within 24 h of CCU admission. Patients were classified as either high nutritional risk (score ≥ 5) or low nutritional risk (score < 5). The primary endpoint was death from any cause. Median follow-up was 272 days (interquartile range 59-588). Kaplan-Meier survival analysis showed that overall survival was significantly worse in the high nutritional risk group (p < 0.001). In the multivariate analysis adjusted for chronic kidney disease, systolic blood pressure, hypoalbuminemia, anemia, and C-reactive protein concentration, mNUTRIC score ≥ 5 was an independent predictor of higher all-cause mortality (adjusted hazard ratio, 2.23; 95% confidence interval, 1.33-3.72; p = 0.003). mNUTRIC score ≥ 5 at admission to the CCU is associated with increased risk of mortality in AHF patients in the CCU.
- Open Access
Contemporary clinical characteristics and management patterns in hypertrophic cardiomyopathy: insights from baseline enrolment data in a nationwide prospective Japanese registry
Background The Japanese Hypertrophic Cardiomyopathy Registry Study was designed to provide comprehensive, real-world insights into the clinical characteristics and management of hypertrophic cardiomyopathy (HCM) in Japan. Methods This multicentre, prospective study enrolled consecutive patients with HCM from 24 referral hospitals across Japan starting in 2016. The baseline characteristics of 1485 patients enrolled by December 2019 are presented in this analysis. Results The median ages at registration and diagnosis were 69 and 60 years, respectively, with men accounting for 54% of the cohort. Familial HCM was confirmed in 18% of cases. Of the cohort, 36% had hypertrophic obstructive cardiomyopathy (HOCM), while 8% had mid-ventricular obstruction, 14% had apical HCM and 4% were in the end-stage phase. Atrial fibrillation was observed in 27% of patients, though the majority were asymptomatic or had mild symptoms at registration. Adverse outcomes included prior sustained ventricular tachycardia or fibrillation (6%), heart failure requiring hospitalisation (11%) and embolic events (5%). Defibrillator implantation was performed in 11% of patients. Differences in the defibrillator indications for primary prevention in the current three guidelines and status of defibrillator deployment at registration were clarified: the percentages of class IIa recommendation in the whole cohort and of patients with defibrillator implantation in class IIa were 22% and 19% in the Japanese guidelines, 4% and 39% in the European guidelines and 28% and 22% in the American guidelines, respectively. Beta blockers were prescribed to 90% of patients with HOCM, while 51% received cibenzoline. Septal reduction therapies were performed in 22% of patients with HOCM, with 6% undergoing surgical myectomy. Conclusions As the first large-scale, prospective HCM registry in Japan, this study provides valuable baseline data on the clinical characteristics and management of HCM. These findings will help address gaps between current practice and guideline recommendations, improving the care of patients with HCM.
Open AccessContemporary clinical characteristics and management patterns in hypertrophic cardiomyopathy: insights from baseline enrolment data in a nationwide prospective Japanese registry
Background The Japanese Hypertrophic Cardiomyopathy Registry Study was designed to provide comprehensive, real-world insights into the clinical characteristics and management of hypertrophic cardiomyopathy (HCM) in Japan. Methods This multicentre, prospective study enrolled consecutive patients with HCM from 24 referral hospitals across Japan starting in 2016. The baseline characteristics of 1485 patients enrolled by December 2019 are presented in this analysis. Results The median ages at registration and diagnosis were 69 and 60 years, respectively, with men accounting for 54% of the cohort. Familial HCM was confirmed in 18% of cases. Of the cohort, 36% had hypertrophic obstructive cardiomyopathy (HOCM), while 8% had mid-ventricular obstruction, 14% had apical HCM and 4% were in the end-stage phase. Atrial fibrillation was observed in 27% of patients, though the majority were asymptomatic or had mild symptoms at registration. Adverse outcomes included prior sustained ventricular tachycardia or fibrillation (6%), heart failure requiring hospitalisation (11%) and embolic events (5%). Defibrillator implantation was performed in 11% of patients. Differences in the defibrillator indications for primary prevention in the current three guidelines and status of defibrillator deployment at registration were clarified: the percentages of class IIa recommendation in the whole cohort and of patients with defibrillator implantation in class IIa were 22% and 19% in the Japanese guidelines, 4% and 39% in the European guidelines and 28% and 22% in the American guidelines, respectively. Beta blockers were prescribed to 90% of patients with HOCM, while 51% received cibenzoline. Septal reduction therapies were performed in 22% of patients with HOCM, with 6% undergoing surgical myectomy. Conclusions As the first large-scale, prospective HCM registry in Japan, this study provides valuable baseline data on the clinical characteristics and management of HCM. These findings will help address gaps between current practice and guideline recommendations, improving the care of patients with HCM.
- 9 September 2024
- Published by Elsevier in Journal of Cardiology
- Vol. 85 (4) , 309-314
Relationship between left atrial/left ventricular diameter ratio and outcomes in patients with hypertrophic cardiomyopathy
- 9 September 2024
- Published by Elsevier in Journal of Cardiology
- Vol. 85 (4) , 309-314
Relationship between left atrial/left ventricular diameter ratio and outcomes in patients with hypertrophic cardiomyopathy
- 10 July 2024
- Published by Springer Nature in Heart and Vessels
- Vol. 40 (1) , 55-61
Relationship between the HeartMate Risk Score category on admission and outcome in patients with acute heart failure referred to a cardiac intensive care unit
The HeartMate Risk Score (HMRS), a simple clinical prediction rule based on the patients’ age, albumin, creatinine, and the international normalized ratio of the prothrombin time (PT-INR), is correlated with mortality in the cohort of left ventricular assist device (LVAD) recipients. However, in an aging society, an LAVD is indicated for only a small proportion of patients with acute heart failure (AHF), and whether the HMRS has prognostic implications for unselected patients with AHF is unknown. This study aimed to assess the prognostic value of HMRS categories on admission in patients with AHF. We analyzed 339 hospitalized patients with AHF who had albumin, creatinine, and the PT-INR recorded on admission. The patients were categorized as follows: the High group (HMRS > 2.48, n = 131), Mid group (HMRS of 1.58–2.48, n = 97) group, and Low group (HMRS < 1.58, n = 111). The endpoints of this study were all-cause death and readmission for heart failure (HF). During a median follow-up of 247 days, 24 (18.3%) patients died in the High group, 7 (7.2%) died in the Mid group, and 8 (7.2%) died in the Low group. In a multivariable analysis adjusted for highly imbalanced baseline variables, a high HMRS was independently associated with survival, with a hazard ratio of 2.90 (95% confidence interval 1.42–5.96, P = 0.004). With regard to the composite endpoint of all-cause death and readmission for HF, the Mid group had a worse prognosis than the Low group, and the High group had the worst prognosis. A high HMRS on admission is associated with all-cause mortality and readmission for HF, and a mid-HMRS is associated with readmission for HF after AHF hospitalization. The HMRS may be a valid clinical tool to stratify the risk of adverse outcomes after hospitalization in unselected patients with AHF.
- 10 July 2024
- Published by Springer Nature in Heart and Vessels
- Vol. 40 (1) , 55-61
Relationship between the HeartMate Risk Score category on admission and outcome in patients with acute heart failure referred to a cardiac intensive care unit
The HeartMate Risk Score (HMRS), a simple clinical prediction rule based on the patients’ age, albumin, creatinine, and the international normalized ratio of the prothrombin time (PT-INR), is correlated with mortality in the cohort of left ventricular assist device (LVAD) recipients. However, in an aging society, an LAVD is indicated for only a small proportion of patients with acute heart failure (AHF), and whether the HMRS has prognostic implications for unselected patients with AHF is unknown. This study aimed to assess the prognostic value of HMRS categories on admission in patients with AHF. We analyzed 339 hospitalized patients with AHF who had albumin, creatinine, and the PT-INR recorded on admission. The patients were categorized as follows: the High group (HMRS > 2.48, n = 131), Mid group (HMRS of 1.58–2.48, n = 97) group, and Low group (HMRS < 1.58, n = 111). The endpoints of this study were all-cause death and readmission for heart failure (HF). During a median follow-up of 247 days, 24 (18.3%) patients died in the High group, 7 (7.2%) died in the Mid group, and 8 (7.2%) died in the Low group. In a multivariable analysis adjusted for highly imbalanced baseline variables, a high HMRS was independently associated with survival, with a hazard ratio of 2.90 (95% confidence interval 1.42–5.96, P = 0.004). With regard to the composite endpoint of all-cause death and readmission for HF, the Mid group had a worse prognosis than the Low group, and the High group had the worst prognosis. A high HMRS on admission is associated with all-cause mortality and readmission for HF, and a mid-HMRS is associated with readmission for HF after AHF hospitalization. The HMRS may be a valid clinical tool to stratify the risk of adverse outcomes after hospitalization in unselected patients with AHF.